Trial record 1 of 1 for:    nifurtimox and medulloblastoma
Previous Study | Return to List | Next Study

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

This study is currently recruiting participants.
Verified February 2014 by Spectrum Health Hospitals
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Giselle Sholler, Spectrum Health Hospitals
ClinicalTrials.gov Identifier:
NCT00601003
First received: January 14, 2008
Last updated: February 5, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)